Bioxytran Announces Distribution Deal for A-SUQAR Supplement

Biotech firm partners with Khoury Medical to commercialize its proprietary blood sugar management product.

Published on Feb. 19, 2026

Got story updates? Submit your updates here. ›

Bioxytran, Inc., a biotechnology company developing carbohydrate-based technologies, has entered into a commercial distribution agreement with Khoury Medical LTD to commercialize A-SUQAR, a chewable dietary supplement containing Bioxytran's proprietary partially hydrolyzed guar gum (PHGG) formulation. The agreement allows Khoury Medical to market and distribute the product in permitted markets, while Bioxytran maintains ownership of the intellectual property.

Why it matters

This deal represents a milestone for Bioxytran as it transitions from a development-stage organization to one with recurring commercial revenue. A-SUQAR provides real-world validation of the company's proprietary carbohydrate-based galectin platform, which also underpins its pharmaceutical development programs, demonstrating the broad potential of this technology.

The details

Under the agreement, Khoury Medical will commercialize A-SUQAR, a dietary supplement intended to support healthy post-meal blood sugar levels. Manufacturing will be performed by Bioxytran's designated OEM, while Khoury Medical will handle regulatory registration, marketing, and distribution. The deal provides the potential for earned, volume-based marketplace exclusivity for Khoury Medical, subject to certain conditions.

  • The agreement was announced on February 17, 2026.
  • The parties expect initial commercial shipments to commence following completion of standard launch preparations.

The players

Bioxytran, Inc.

A biotechnology company developing carbohydrate-based technologies targeting galectins and related biological pathways, with potential applications across infectious disease, metabolic health, inflammation, and oncology.

Khoury Medical LTD

A health-focused company dedicated to the development and commercialization of plant-derived dietary supplements, partnering with innovative technology providers to bring differentiated, science-driven products to market.

David Platt

Chief Executive Officer of Bioxytran.

Nassar Khoury

CEO of Khoury Medical LTD.

Got photos? Submit your photos here. ›

What they’re saying

“This agreement represents an important milestone for Bioxytran as we transition from a development-stage organization to a company with recurring commercial revenue.”

— David Platt, Chief Executive Officer of Bioxytran (dispurnewsflash.com)

“This collaboration allows us to bring a differentiated, science-informed product with the potential for broader market expansion, subject to applicable agreements and regulatory requirements.”

— Nassar Khoury, CEO of Khoury Medical LTD (dispurnewsflash.com)

What’s next

The parties expect initial commercial shipments of A-SUQAR to commence following completion of standard launch preparations.

The takeaway

This distribution agreement demonstrates Bioxytran's ability to leverage its proprietary carbohydrate-based galectin platform to generate commercial revenue, while preserving the company's focus on advancing higher-value pharmaceutical and antiviral programs.